Crohn's disease: future anti-tumor necrosis factor therapies beyond infliximab

被引：10
|
作者：
Korzenik, JR [1 ]
机构：
[1] Massachusetts Gen Hosp, Dept Internal Med, Gastrointestinal Unit, Boston, MA 02114 USA
来源：
GASTROENTEROLOGY CLINICS OF NORTH AMERICA | 2004年 / 33卷 / 02期
关键词：
D O I：
10.1016/j.gtc.2004.02.009
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
The dramatic benefit experienced by many Crohn's patients treated with the anti-tumor necrosis factor-alpha (TNF-alpha) antibody infliximab underscores the centrality of this cytokine in the pathogenesis of Crohn's disease and the potential use of the therapeutic strategy of blocking TNF-alpha in this disease. In the hopes of emulating and improving on the success of infliximab, numerous strategies are being devised and studied to inhibit the actions of TNF-alpha. This article focuses on those agents, other than infliximab, which target TNF-alpha to treat inflammatory bowel disease as their central mechanism of action.
引用
收藏
页码：285 / +
页数：18
相关论文
共 50 条
  • [1] Demyelination during anti-tumor necrosis factor α therapy with infliximab for Crohn's disease
    Thomas, CW
    Weinshenker, BG
    Sandborn, WJ
    INFLAMMATORY BOWEL DISEASES, 2004, 10 (01) : 28 - 31
  • [2] Anti-tumor necrosis factor agents in Crohn's disease and ulcerative colitis: Beyond luminal disease
    Nunez-Gomez, Laura
    Mesonero-Gismero, Francisco
    Albillos-Martinez, Agustin
    Lopez-Sanroman, Antonio
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2018, 41 (09): : 576 - 582
  • [3] Effect of Anti-Tumor Necrosis Factor-a Therapies on Tissue Markers of Crohn's Disease Phenotypes
    Nemeth, Zoltan H.
    Kong, Karen
    Rolandelli, Rolando H.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2020, 231 (04) : S52 - S53
  • [4] REAL WORLD DOSING OF ANTI-TUMOR NECROSIS FACTOR THERAPIES IN THE TREATMENT OF ADULTS WITH CROHN'S DISEASE
    Waters, H.
    Meekins, T.
    Bewtra, A.
    McKenzie, R. S.
    Tang, B.
    Piech, C. T.
    Papandrikopoulou, N.
    VALUE IN HEALTH, 2008, 11 (06) : A523 - A523
  • [5] Real world dosing of anti-tumor Necrosis factor therapies in the treatment of adults with Crohn's Disease
    Waters, H.
    Meekins, T.
    Bewtra, A.
    McKenzie, R.
    Tang, B.
    Piech, C.
    INFLAMMATORY BOWEL DISEASES, 2008, 14 (12) : S4 - S4
  • [6] Real world dosing of anti-tumor necrosis factor therapies in the treatment of adults with Crohn's disease
    Waters, H.
    Meekins, T.
    Bewtra, A.
    McKenzie, R.
    Tang, B.
    Piech, C.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 : S393 - S393
  • [7] Treatment of pediatric Crohn's disease (CD) with anti-tumor necrosis factor α chimeric monoclonal antibody (infliximab)
    Kugathansan, S
    Rivera, MT
    Martinez, A
    Binion, DG
    Werlin, SL
    GASTROENTEROLOGY, 1999, 116 (04) : A755 - A755
  • [8] Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
    Rutgeerts, P
    D'Haens, G
    Targan, S
    Vasiliauskas, E
    Hanauer, SB
    Present, DH
    Mayer, L
    Van Hogezand, RA
    Braakman, T
    DeWoody, KL
    Schaible, TF
    Van Deventer, SJH
    GASTROENTEROLOGY, 1999, 117 (04) : 761 - 769
  • [9] Tumor Necrosis Factor and Anti-Tumor Necrosis Factor Therapies
    Keystone, Edward C.
    Ware, Carl F.
    JOURNAL OF RHEUMATOLOGY, 2010, 37 : 27 - 39
  • [10] Management of Inflammatory Bowel Disease with Infliximab and Other Anti-Tumor Necrosis Factor Alpha Therapies
    Fernando Magro
    Francisco Portela
    BioDrugs, 2010, 24 : 3 - 14
12345